SERUM LEVEL OF INTERLEUKIN-16 IN PREECLAMPSIA

Thesis

Submitted for Partial Fulfillment of Master Degree In Obstetrics and Gynecology

Presented by Shimaa Gaballah El-Desoky

M.B.B. Ch, Ain Shams University

Under Supervision of

Dr./ Yasser Mohamed Abou-Talib

Assisstant Professor of Obstetrics and Gynecology Faculty of Medicine – Ain Shams University

Dr./ Tarek Aly Raafat

Lecturer of Obstetrics and Gynecology Faculty of Medicine – Ain Shams University

Faculty of Medicine Ain Shams University 2009

Acknowledgement

First and foremost, thanks and grateful to **ALLAH** for giving me the power and strength to carry out this work.

Words do fail to express my deepest gratitude and appreciation to **Dr. Yaser Mohammed Abu Taleb**, Assistant Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, for his excellent guidance ,powerful support, supervision and help through out the accomplishment of this study. I owe him more than I can express for all his big efforts in bringing this work to light.

It is a great honour for me to take this opportunity to express my most profound gratitude, deep respect and appreciation to **Dr. Tarek Aly Raafat**, Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University for his for the immeasurable time and effort devoted for the revision, encouragement and correction of the manuscript. I owe him more than I can express for all the so long time he spent in revising every detail.

I would like to thank **specialists, technical staff in the Allergy and Immunology Center**, Faculty of Medicine, Al-Azhar University for their help and assistance offered during carry out the practical part of the study.

I would like also sincerely to thank all my **Professors and Colleagues in the Obstetrics and Gynecology Department**, for the support and overwhelming care with which they surrounded me. Last but not least, my true love goes to all my family, who were, and will always be, by my side and without whom I would have never been able to accomplish this work.

Shimaa Gaballa

Dedicated to



Contents

Page
List of Abbreviations
List of Tables, Figures and GraphicsII
Introduction1
Aim of the work5
Review of Literature
I - Preeclampsia6
- Historical background
- Classification of preeclampsia9
- Clinical manifestations of preeclampsia
- Hypertension
- Renal dysfunction and proteinuria
- Edema
 Hyperuricemia
- Coagulation abnormalities and HELLP syndrome19
- Pathophysiology and molecular mechanisms20
- The placenta and preeclampsia
- Trophoblast invasion at interface 124
- Abnormal placentation29
- Endothelial dysfunction
- Endoglin
- Management of preeclampsia
Prevention of preeclampsia
- Long-term effects of preeclampsia51
II - Cytokines
- Interleukin-16
- Cells of origin
- IL-16 in inflammation
- Immunoregulation in normal pregnancy and preeclampsia63 - Normal pregnancy and inflammation 66
 Normal pregnancy and inflammation
- Cytokines in preeclampsia70
- Cytokines and the maternal symptoms
- Subjects, Materials and Method
- Results 83
- Disscussion
- Summary and conclusion117
- Recommendation121
- References
-Arabic Summary

List of Abbreviations

Abbreviation	Full Meaning
ALT	: Alanine transaminase
AST	: Aspartate transaminase
AT1-B2	: Angiotensin II receptor type 1 and bradykinin B2
	receptor
CD	: Cluster of differentiation
Eng	: Endoglin
GFR	: Glomerular filtration rate
HELLP	: Hemolysis, elevated liver enzymes, low platelet
	count
HLA	: Human leucocyte antigen
IFN	: Interferon
IL	: Interleukin
IL2R α	: IL -2 receptor alpha
MHC	: Major histocompatibility complex
NIL-16	: Neuronal form of IL-16
NK cells	: Natural killer cells
NO	: Nitric oxide
NOS	: Nitric oxide synthase
PGI2	: Prostaglandin I 2
PIGF	: Placental growth factor
ROS	: Reactive oxygen species
RPF	: Renal plasma flow
sEng	: Soluble endoglin
SFlt1	: Soluble fms-like tyrosine kinase 1
SOD	: Superoxide dismutase
TCR	: T cell receptor
TGFB3	: Transforming growth factor B3
Thl	: T-helper type 1
Th2	: T-helper type 2
TNF α	: Tumor necrosis factor alpha
TX A2	: Thromboxane A2
VEGR	: Vascular endothelial growth factor

__

List of tables

page
Table 1: Risk Factors for Preeclampsia
Table 2: Indications for delivery in preeclampsia
Table 3: Characteristic of the study groups:
Table 4 (Cont.)
Table 5: Distribution of proteinuria among the study groups :
Table 6: Comparison between the three groups as regards the mean age85
Table 7: Comparison between the three groups as regards the mean gestational age
Table 8: Comparison between the three groups as regards the mean systolic and diastolic blood pressure
Table 9: Multiple Comparisons. 89
Table 10: Comparison between the three groups as regards the mean Hb, platelets, AST, ALT and creatinine:
Table 11: Multiple Comparisons
Table 12: Comparison between the three groups as regards the mean IL-16
Table 13: Multiple Comparisons
Table 14: Comparison between the three groups as regards the proteinuria
Table 15: Comparison between the proteinuria in cases of mild and severe preeclampsia as regards the mean IL-16
Table 16: Multiple Comparisons
Table 17: Correlation between IL- 16 and Systolic and diastolic blood pressure, Hb, Platelets, AST, ALT and Serum Creatinine in cases of pre-eclampsia (60)

--

List of Figures

<u>page</u>
Figure 1: An algorithm for differentiating among hypertensive disorders in pregnant women
Figure 2: Kidney specimen from a preeclamptic patient
Figure 3: Electron microscopy of a glomerulus from a preeclamptic patient 17
Figure 4: Diagram of the fetal–maternal interface
Figure 5: Diagram of the utero–placental interface in the first trimester and later in pregnancy
Figure 6: Diagram of abnormalities of cytotrophoblast invasion
Figure 7: Scatter diagram of IL- 16 and systolic blood pressure
Figure 8: Scatter diagram of IL- 16 and Hb
Figure 9: Scatter diagram of IL- 16 and platelets
Figure 10: Scatter diagram of IL- 16 and serum creatinine
Figure 11: Receiver Operating Characteristic (ROC) curve to define the best cut off to IL-16 to detect preeclampsia

--

List of Graphics

	page
Graph (1): Comparison between the three groups as regards the mean systolic and diastolic blood pressure	
Graph(2): Comparison between the three groups as regards the mean Hb	95
Graph(3): Comparison between the three groups as regards the mean platelets	95
	96
Graph(4): Comparison between the three groups as regards the mean AST	
Graph(5): Comparison between the three groups as regards the mean ALT	96
Graph (6): Comparison between the three groups as regards the mean creatinine	97
Graph (7) : Comparison between the three groups as regards the mean IL-16	99
Graph (8): Correlation between the proteinuria and the mean IL-16	102

--

Introduction

Preeclampsia is a heterogeneous disorder affecting 3–5% of pregnancies and a major cause of obstetric morbidity and mortality worldwide. For the fetus, preeclampsia can result in small-for-gestational-age infancy, preterm delivery, hypoxic neurologic injury or death. For the mother, complications of preeclampsia include renal failure, HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), seizures, liver failure, stroke or death. Women with preeclampsia often later develop cardiovascular disease and hypertension, another source of significant morbidity (*Redman and Sargent*, 2005).

While the initial events involved in the pathogenesis of pre-eclampsia are still a mystery, recent developments have begun to elucidate molecular mechanisms behind its manifestations. Scientists have postulated many theories regarding its cause, but the pathogenesis remains poorly understood (*Saftlas et al.*, 2005).

An abnormally developed, hypoxic placenta and endothelial dysfunction are important themes. Further, there seems to be a tip in the balance of angiogenesis versus antiangiogenesis, with favoring of the latter in pre-eclampsia. The mechanism of endothelial activation is unknown but may result from inflammatory cytokines produced by the placenta caused by ischemia or injury of the endothelium. Serum levels

of several cytokines have been reported to be altered and the alterations in cytokine levels were thought to participate the pathogenesis of preeclampsia (*Matthiesen et al.*, 2005).

Cytokines are small immunologic "hormones" that recruit other immune cells, cause oxidative stress, and may contribute the endothelial damage. Several studies have implicated abnormal levels of cytokines in preeclampsia, but the pattern of cytokine expression and a possible role in its pathogenesis remains controversial. Cytokine responses are generally characterized as T-helper type 1 (Thl) or type 2 (Th2). It is generally agreed that preeclampsia is associated with both local and systemic changes in type 1/type 2 cytokine balance compared to normal pregnancy. Decidual lymphocytes and peripheral blood mononuclear cells from patients with preeclampsia are generally primed to synthesize high levels of the Th1 cytokines, interleukin (IL)-2, IL-12, and IFN-γ. On the other hand, they exhibit low spontaneous or phytohemaglutinininduced expression of the Th2 cytokines IL-10 and IL-5 (Jonsson et al., 2005).

Inflammatory cytokines are peptide mediators of endothelial cell activation and dysfunction and have been speculated to have arole in the pathogenesis of preeclampsia because of their endothelial effect (*Matthiesen et al.*, 2005).

Whereas these findings initially lead to the conclusion that a maternal T lymphocyte- mediated cytotoxic reaction against the fetal allograft was possibly associated with, and may be the cause of preeclampsia, it is now believed that such a cytokine environment rather reflects the state of exaggerated inflammation that characterizes the disease. Monocytes and granulocytes present an activated pattern of leukocyte adhesion molecules on their surface and show an increased incidence of basal or induced oxidative stress response compared to their counterparts from normal pregnancy. Spontaneous monocytic cytokine expression is higher in preeclampsia in comparison with normal pregnancy (*Luppi and Deloia*, 2006).

Interleukin-16 was initially described as a T-lymphocyte chemoattractant using cluster of differentiation type 4 (CD4) as its receptor. IL-16 stimulates the production of proinflammatory cytokines such as IL-6, tumor necrosis factor alpha (TNF- α), IL-1 alpha and IL-15 by monocytes, and upregulation of IL -2 receptor alpha (IL-2R alpha) on T cells. In addition, IL-16 inhibits IL-4 and IL-5 release from T cells and thus impairs Th2 immunity (*Pinsonneault et al.*, 2001).

Interleukin -16 is expressed in numerous normal human tissues and cell types, including activated monocytes, dendritic cells and fibroblasts (*Lynch et al.*, 2003).

On the other hand, serum level of IL -16 is increased in inflammatory conditions, such as systemic lupus erythematousus, rheumatoid arthritis, allergic diseases and inflammatory bowel disease (*Karaki et al, 2005 and Seegert & Schreiber, 2000*).

In addition, a bias towards Th1 immunity exists in preeclampsia (*Saito and Sakai*, 2003), while IL-16 alters the Th1/Th2 balance by inhibiting Th2 immunity (*Pinsonneault et al.*, 2001).

Aim of the Work

The purpose of the current study is to evaluate the relationship between the serum level of interleukin -16 and preeclampsia in pregnant females.

I - Preeclampsia

Preeclampsia is a serious complication of the second half of human pregnancy, which can have harmful effects on the immediate and long-term health of the mother and the baby (Sibai et al., 2005).

This disease is characterized by multiple maternal disturbances, among which the more prominent symptoms are de novo hypertension, proteinuria, and edema. Additional metabolic dysfunctions may be present, such as activation of the clotting system, impaired liver function, renal failure or pulmonary edema, in particular, in cases of severe, early onset disease (*Von-Dadelszen et al.*, 2003).

In the absence of intervention, preeclampsia can progress in generalized convulsions or eclampsia. The symptoms resolve only once the placenta is removed, and thus, preeclampsia remains one of the most common reasons for induced preterm delivery. While the etiology of the disorder is still elusive, it is quite clear that it requires a placenta to develop. Risk factors are known and include primiparity, multiple pregnancies, a previous history of preeclampsia, and chronic medical conditions such as obesity, hypertension, vascular disease, or diabetes (*Duckitt and Harrington*, 2005).

However, there is no definitive predictive factor and no preventive treatment available so far. There may undoubtedly be a genetic component at the basis of some cases of preeclampsia, at least in those with a familial history (*Laivuori*, 2007).

However, such a genetic cause has not been convincingly demonstrated until now, most likely because polymorphisms in not only one but in several genes are likely to predispose to the development of this complex multifactorial disease. On the other hand, recent work clearly reveals that immune maladaptation and overt activation of the maternal innate immune system are involved in preeclampsia (*Sargent et al.*, 2006).

Remarkably, although the maternal symptoms of preeclampsia appear very heterogeneous at first sight, they can all be ascribed to a generalized endothelium dysfunction, which is undeniably part of this exaggerated systemic inflammatory response to pregnancy (*Redman and Sargent*, 2003).

Historical Background

Since the 18th century, preeclampsia has been known and termed under such headings as puerperal convulsions, puerperal nephritis and albuminuria, puerperal albuminuria and convulsions, eclampsia, toxemia and preeclamptic toxemia and as pregnancy associated hypertension or hypertensive disease in pregnancy (*Chesley*, 1976).